STARPharmaceuticals
Strides Pharma Science Ltd — Profit & Loss Statement
₹937.75
+1.19%
Strides Pharma Science Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 17.73 Cr | -46.97 Cr | -2.50 Cr | -64.28 Cr | — |
| Tax Rate For Calcs | 0.18 | 0.30 | 0.19 | 0.27 | — |
| Normalized EBITDA | 790.26 Cr | 500.96 Cr | 187.57 Cr | -38.49 Cr | — |
| Total Unusual Items | 96.36 Cr | -156.56 Cr | -12.93 Cr | -235.29 Cr | — |
| Total Unusual Items Excluding Goodwill | 96.36 Cr | -156.56 Cr | -12.93 Cr | -235.29 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 405.35 Cr | -120.20 Cr | -221.20 Cr | -460.21 Cr | — |
| Reconciled Depreciation | 192.26 Cr | 220.68 Cr | 243.25 Cr | 233.01 Cr | — |
| Reconciled Cost Of Revenue | 2.13K Cr | 1.88K Cr | 1.75K Cr | 1.63K Cr | — |
| EBITDA | 886.61 Cr | 344.40 Cr | 174.64 Cr | -273.77 Cr | — |
| EBIT | 694.35 Cr | 123.72 Cr | -68.61 Cr | -506.79 Cr | — |
| Net Interest Income | -203.48 Cr | -250.58 Cr | -186.63 Cr | -68.29 Cr | — |
| Interest Expense | 207.43 Cr | 238.51 Cr | 217.59 Cr | 145.72 Cr | — |
| Interest Income | 45.37 Cr | 29.64 Cr | 74.51 Cr | 108.45 Cr | — |
| Normalized Income | 326.72 Cr | -10.61 Cr | -210.78 Cr | -289.20 Cr | — |
| Net Income From Continuing And Discontinued Operation | 3.59K Cr | -70.61 Cr | -202.63 Cr | -460.21 Cr | — |
| Total Expenses | 3.81K Cr | 3.41K Cr | 3.46K Cr | 3.26K Cr | — |
| Rent Expense Supplemental | 15.62 Cr | 15.76 Cr | 14.40 Cr | 8.09 Cr | — |
| Diluted Average Shares | 9.20 Cr | 9.11 Cr | 9.01 Cr | 8.98 Cr | — |
| Basic Average Shares | 9.20 Cr | 9.10 Cr | 9.01 Cr | 8.97 Cr | — |
| Diluted EPS | 390.50 | -7.76 | -22.49 | -51.28 | — |
| Basic EPS | 390.55 | -7.76 | -22.49 | -51.28 | — |
| Diluted NI Availto Com Stockholders | 3.59K Cr | -70.61 Cr | -202.63 Cr | -460.21 Cr | — |
| Net Income Common Stockholders | 3.59K Cr | -70.61 Cr | -202.63 Cr | -460.21 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 3.59K Cr | -70.61 Cr | -202.63 Cr | -460.21 Cr | — |
| Minority Interests | -4.06 Cr | 23.70 Cr | 9.70 Cr | 14.04 Cr | — |
| Net Income Including Noncontrolling Interests | 3.60K Cr | -94.31 Cr | -212.33 Cr | -474.25 Cr | — |
| Net Income Discontinuous Operations | 3.19K Cr | 49.59 Cr | 18.57 Cr | 0.00 | — |
| Net Income Continuous Operations | 409.40 Cr | -143.90 Cr | -230.90 Cr | -474.25 Cr | — |
| Tax Provision | 77.52 Cr | 29.11 Cr | -55.30 Cr | -178.26 Cr | — |
| Pretax Income | 486.92 Cr | -114.79 Cr | -286.20 Cr | -652.51 Cr | — |
| Other Non Operating Income Expenses | 6.63 Cr | 7.76 Cr | 10.85 Cr | 13.12 Cr | — |
| Special Income Charges | 96.36 Cr | -156.56 Cr | -12.93 Cr | -235.29 Cr | — |
| Other Special Charges | -91.41 Cr | -4.03 Cr | 26.84 Cr | -40.75 Cr | — |
| Write Off | 50000.00 | 157.51 Cr | 33.04 Cr | 234.21 Cr | — |
| Restructuring And Mergern Acquisition | -4.95 Cr | 3.08 Cr | -46.96 Cr | 41.83 Cr | — |
| Net Non Operating Interest Income Expense | -203.48 Cr | -250.58 Cr | -186.63 Cr | -68.29 Cr | — |
| Total Other Finance Cost | 41.42 Cr | 41.72 Cr | 43.55 Cr | 31.02 Cr | — |
| Interest Expense Non Operating | 207.43 Cr | 238.51 Cr | 217.59 Cr | 145.72 Cr | — |
| Interest Income Non Operating | 45.37 Cr | 29.64 Cr | 74.51 Cr | 108.45 Cr | — |
| Operating Income | 579.60 Cr | 321.08 Cr | 142.88 Cr | -241.75 Cr | — |
| Operating Expense | 1.68K Cr | 1.53K Cr | 1.72K Cr | 1.63K Cr | — |
| Other Operating Expenses | 331.46 Cr | 364.39 Cr | 398.64 Cr | 309.93 Cr | — |
| Depreciation And Amortization In Income Statement | 192.26 Cr | 220.68 Cr | 243.25 Cr | 233.01 Cr | — |
| Amortization | 76.14 Cr | 71.55 Cr | 71.32 Cr | 59.73 Cr | — |
| Depreciation Income Statement | 116.12 Cr | 149.13 Cr | 171.93 Cr | 173.28 Cr | — |
| Selling General And Administration | 423.81 Cr | 317.06 Cr | 411.33 Cr | 482.50 Cr | — |
| Selling And Marketing Expense | 298.20 Cr | 215.03 Cr | 263.65 Cr | 331.30 Cr | — |
| General And Administrative Expense | 125.62 Cr | 102.03 Cr | 147.68 Cr | 151.21 Cr | — |
| Rent And Landing Fees | 15.62 Cr | 15.76 Cr | 14.40 Cr | 8.09 Cr | — |
| Gross Profit | 2.26K Cr | 1.85K Cr | 1.86K Cr | 1.39K Cr | — |
| Cost Of Revenue | 2.13K Cr | 1.88K Cr | 1.75K Cr | 1.63K Cr | — |
| Total Revenue | 4.39K Cr | 3.73K Cr | 3.61K Cr | 3.02K Cr | — |
| Operating Revenue | 4.39K Cr | 3.73K Cr | 3.61K Cr | 3.02K Cr | — |
| Impairment Of Capital Assets | — | 157.51 Cr | 33.04 Cr | 4.68 Cr | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Strides Pharma Science Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.